[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Wednesday, 8 February 2006, 12:32 GMT
Glaxo profit up 17% on good sales
Glaxo's headquarters in London
Key product sales have boosted Glaxo's profits
Strong sales of core medicines have helped GlaxoSmithKline to a 17% rise in 2005 profits, beating stock market expectations.

For the full year to 31 December, the London-based firm saw its pre-tax profit increase to 6.7bn ($11.7bn) from 5.8bn in 2004.

Aided by strong sales of its main Advair asthma drug and other key products, turnover was up to 21.6bn.

The sales were up 7% on the 20bn achieved the year before.

Continuing growth

Sales of Advair were up 22% in 2005 to more than 3bn, while diabetes medication Avandia increased by 18% to 1.3bn.

Vaccines were up 15% to 1.4bn.

Glaxo now predicts 10% profit growth for the current year.

It also gave an eagerly awaited update on its Cervarix cervical cancer vaccine, saying it would file for regulatory approval in Europe next month and in the US by the end of the year.

Drug firm profits beat forecasts
27 Oct 05 |  Business
Strong results pep up drug makers
28 Jul 05 |  Business
FDA agreement lifts Glaxo shares
28 Apr 05 |  Business
GSK investors bring Paxil lawsuit
14 Apr 05 |  Business
GSK aims to stop Aids profiteers
21 Feb 05 |  Business

The BBC is not responsible for the content of external internet sites


Americas Africa Europe Middle East South Asia Asia Pacific